Anti-CD3 Anti-CD20 bispecific antibody (Protheragen)

N/A

Report date: 2026/03/19 17:01:25

Base Information

Drug NameAnti-CD3 Anti-CD20 bispecific antibody (Protheragen)
Drug Alias NameCD3xCD20 bsAb
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 inhibitorsB-lymphocyte antigen CD20 inhibitors
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProtheragen Inc
China Registration ClassN/A

Develop Information

Active CompaniesProtheragen Inc
Inactive CompaniesN/A
Active IndicationsLymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A